Vanda Pharmaceuticals Inc (NASDAQ: VNDA) is a specialty pharmaceutical company that develops and commercializes drugs for central nervous system disorders and other conditions. Revenue comes primarily from product sales of its approved medicines, with royalties and licensing as secondary income streams. The 10-K filed February 12, 2026 (accession 000162828026007460) does not provide sufficient excerpted detail to specify segment revenue breakdowns, key competitors by name, geographic revenue mix, customer concentration figures, or founding and leadership history. Based solely on the available filing excerpts, further specifics on commercial products, market position, and capital structure cannot be confirmed. Any additional detail beyond what the excerpts support has been omitted per source-grounding requirements.

Revenue model

The available filing excerpts do not provide sufficient detail to describe the revenue model with specific figures or product-level breakdowns.

Products and services

Not determinable from the provided filing excerpts.

Customers and end markets

Not determinable from the provided filing excerpts.

Value-chain role

Specialty pharmaceutical developer and commercial-stage drug marketer.

Geographic exposure

Not determinable from the provided filing excerpts.

Source: SEC 10-K, filed 2026-02-12

Industry: Pharmaceutical Preparations Peers: Adicet Bio Inc Agenus Inc Century Therapeutics Inc Cullinan Therapeutics Inc Immunovant Inc Janux Therapeutics Inc Kezar Life Sciences Inc Kinnate Biopharma Inc. PMV Pharmaceuticals Inc